

Correction: Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non-Small Cell Lung Cancer and Its Potential as a Circulating Biomarker



In the original version of this article (1), the Introduction provides an incorrect false-positive rate of lung cancer screening with low-dose computed tomography (CT) as reported in the National Lung Screening Trial (NLST) results. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

Reference

1. Lou T-F, Sethuraman D, Dospoy P, Srivastva P, Kim HS, Kim J, et al. Cancer-specific production of N-acetylaspartate via NAT8L overexpression in non-small cell lung cancer and its potential as a circulating biomarker. *Cancer Prev Res* 2016;9:43–52.

Published online September 5, 2019.

Cancer Prev Res 2019;XX:XX

doi: 10.1158/1940-6207.CAPR-19-0392

©2019 American Association for Cancer Research.

Cancer Prevention Research

Correction: Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non –Small Cell Lung Cancer and Its Potential as a Circulating Biomarker

Cancer Prev Res Published OnlineFirst September 5, 2019.

Updated version Access the most recent version of this article at:
doi:[10.1158/1940-6207.CAPR-19-0392](https://doi.org/10.1158/1940-6207.CAPR-19-0392)

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/early/2019/09/04/1940-6207.CAPR-19-0392>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.